Login to Your Account

‘Month’ to the Flame: Backers Put $20M More into Versartis

By Randy Osborne
Staff Writer

Tuesday, October 8, 2013
Versartis Inc., which holds worldwide rights to the long-acting recombinant human growth hormone (rHGH) VRS-317, may take the treatment for growth hormone deficiency (GHD) all the way to approval and marketing by itself, said Srinivas Akkaraju, general partner with Sofinnova Ventures, a new investor in the company’s $20 million Series D round.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription